143. Lawal, I.; Ebenhan, T.; Mahapane, J.; Vorster, M.; Mokoala, K.; Meckel, M.; Rosch, F.; Sathekge, M. Assessment of Skeletal Metastasis in Prostate Cancer Staging: An Intra-Individual Comparison of ⁶⁸Ga-PSMA PET/CT, ⁶⁸Ga-NODAGA-Zoledronate PET/CT, and ⁹⁹mTc-MDP Bone Scan. *J. Nucl. Med.* **2020**, *61*, 1256.

144. Lawal, I.O.; Mokoala, K.M.G.; Mahapane, J.; Kleyhans, J.; Meckel, M.; Vorster, M.; Ebenhan, T.; Rösch, F.; Sathekge, M.M. A Prospective Intra-Individual Comparison of [⁶⁸Ga]Ga-PSMA-11 PET/CT, [⁶⁸Ga]Ga-NODAGAZOL PET/CT, and [⁹⁹mTc]Tc-MDP Bone Scintigraphy for Radionuclide Imaging of Prostate Cancer Skeletal Metastases. *Eur. J. Nucl. Med. Mol. Imaging* **2021**, *48*, 134–142. [CrossRef]

145. Ndlovu, H.; Lawal, I.; Popoola, G.; Brits, B.; Mokoala, K.; Mahapane, J.; Davis, C.; Sathekge, M. PET Imaging of Atherosclerotic Plaque Calcification with [⁶⁸Ga]Ga-NODAGAZOL: Correlation of Uptake with Cardiovascular Risk Profile of Patients. *J. Nucl. Med.* **2022**, *63*, 2222.

146. Ndlovu, H.; Lawal, I.O.; Popoola, G.O.; Brits, B.; Mokoala, K.M.G.; Maserumule, L.C.; Hlongwa, K.N.; Mahapane, J.; Davis, C.; Sathekge, M.M. [⁶⁸Ga]Ga-NODAGAZOL Uptake in Atherosclerotic Plaques Correlates with the Cardiovascular Risk Profile of Patients. *Ann. Nucl. Med.* **2022**, *36*, 684–692. [CrossRef] [PubMed]

147. Fersing, C.; Bouhlel, A.; Cantelli, C.; Garrigue, P.; Lisowski, V.; Guillet, B. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [¹⁸F]Fluoride: Will [¹⁸F]AlF Replace 68Ga for Metal Chelate Labeling? *Molecules* **2019**, *24*, 2866. [CrossRef] [PubMed]

148. Hassan, H.; Othman, M.F.; Abdul Razak, H.R.; Zakaria, Z.A.; Ahmad Saad, F.F.; Osman, M.A.; Yi, L.H.; Ashhar, Z.; Idris, J.; Abdul Hamid, M.H.N.; et al. Preparation, Optimisation, and In Vitro Evaluation of [¹⁸F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET. *Molecules* **2022**, *27*, 7969. [CrossRef] [PubMed]

149. Fersing, C.; Masurier, N.; Rubira, L.; Deshayes, E.; Lisowski, V. AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. *Pharmaceuticals* **2022**, *15*, 234. [CrossRef]

150. Wu, Z.; Zha, Z.; Choi, S.R.; Plössl, K.; Zhu, L.; Kung, H.F. New 68Ga-PhenA Bisphosphonates as Potential Bone Imaging Agents. *Nucl. Med. Biol.* **2016**, *43*, 360–371. [CrossRef]

151. Kubícek, V.; Rudovský, J.; Kotek, J.; Hermann, P.; Vander Elst, L.; Muller, R.N.; Kolar, Z.I.; Wolterbeek, H.T.; Peters, J.A.; Lukes, I. A Bisphosphonate Monoamide Analogue of DOTA: A Potential Agent for Bone Targeting. *J. Am. Chem. Soc.* **2005**, *127*, 16477–16485. [CrossRef]

152. Fellner, M.; Biesalski, B.; Bausbacher, N.; Kubícek, V.; Hermann, P.; Rösch, F.; Thews, O. ⁶⁸Ga-BPAMD: PET-Imaging of Bone Metastases with a Generator Based Positron Emitter. *Nucl. Med. Biol.* **2012**, *39*, 993–999. [CrossRef]

153. Fellner, M.; Baum, R.P.; Kubícek, V.; Hermann, P.; Lukes, I.; Prasad, V.; Rösch, F. PET/CT Imaging of Osteoblastic Bone Metastases with ⁶⁸Ga-Bisphosphonates: First Human Study. *Eur. J. Nucl. Med. Mol. Imaging* **2010**, *37*, 834. [CrossRef]

154. Mueller, D.; Klette, I.; Baum, R. Clinical Routine Production of ¹⁷⁷Lu-BPAMD. *J. Nucl. Med.* **2013**, *54*, 1191.

155. Meckel, M.; Nauth, A.; Timpe, J.; Zhernosekov, K.; Puranik, A.D.; Baum, R.P.; Rösch, F. Development of a [177Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy. *Cancer Biother. Radiopharm.* **2015**, *30*, 94–99. [CrossRef] [PubMed]

156. Bergmann, R.; Meckel, M.; Kubícek, V.; Pietzsch, J.; Steinbach, J.; Hermann, P.; Rösch, F. ¹⁷⁷Lu-Labelled Macrocyclic Bisphosphonates for Targeting Bone Metastasis in Cancer Treatment. *EJNMMI Res.* **2016**, *6*, 5. [CrossRef] [PubMed]

157. Fellner, M.; Baum, R.; Kubicek, V.; Hermann, P.; Roesch, F. ¹⁷⁷Lu-BPAMD—From Bone Imaging to Therapy with a Macrocycle-Bisphosphonate Ligand. *J. Nucl. Med.* **2010**, *51*, 1164.

158. Pfannkuchen, N.; Meckel, M.; Bergmann, R.; Bachmann, M.; Bal, C.; Sathekge, M.; Mohnike, W.; Baum, R.P.; Rösch, F. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. *Pharmaceuticals* **2017**, *10*, 45. [CrossRef] [PubMed]

159. Yousefnia, H.; Zolghadri, S.; Sadeghi, H.R.; Naderi, M.; Jalilian, A.R.; Shanehsazzadeh, S. Preparation and Biological Assessment of 177Lu-BPAMD as a High Potential Agent for Bone Pain Palliation Therapy: Comparison with ¹⁷⁷Lu-EDTMP. *J. Radioanal. Nucl. Chem.* **2016**, *307*, 1243–1251. [CrossRef]

160. Meckel, M.; Kubíček, V.; Hermann, P.; Miederer, M.; Rösch, F. A DOTA Based Bisphosphonate with an Albumin Binding Moiety for Delayed Body Clearance for Bone Targeting. *Nucl. Med. Biol.* **2016**, *43*, 670–678. [CrossRef] [PubMed]

161. Velikyan, I. Prospective of ⁶⁸Ga-Radiopharmaceutical Development. *Theranostics* **2013**, *4*, 47–80. [CrossRef]

162. Wang, Y.; Wang, Q.; Chen, Z.; Yang, J.; Liu, H.; Peng, D.; Lei, L.; Liu, L.; Wang, L.; Xing, N.; et al. Preparation, Biological Characterization and Preliminary Human Imaging Studies of ⁶⁸Ga-DOTA-IBA. *Front. Oncol.* **2022**, *12*, 1027792. [CrossRef]

163. Yang, J.; Deng, J.; Fan, D.; Chen, G.; Lu, Z.; Liu, H.; Mok, G.S.P.; Chen, Y. Biodistribution and Internal Dosimetry of 68Ga-DOTA-IBA PET Imaging for Patients with Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 847–852. [CrossRef]

164. Wang, Q.; Yang, J.; Wang, Y.; Liu, H.; Feng, Y.; Qiu, L.; Chen, Y. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. *Mol. Pharm.* **2023**, *20*, 1788–1795. [CrossRef]

165. Qiu, L.; Wang, Y.; Liu, H.; Wang, Q.; Chen, L.; Liu, L.; Wang, L.; Feng, Y.; Chen, Y. Safety and Efficacy of 68Ga- or ¹⁷⁷Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases: A Phase 0/I Study. *Clin. Nucl. Med.* **2023**, *48*, 489. [CrossRef] [PubMed]

166. Li, H.; Xu, T.; Hua, Q.; Wang, L.; Chen, Y. 177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 740. [CrossRef] [PubMed]
143. Lawal, I.; Ebenhan, T.; Mahapane, J.; Vorster, M.; Mokoala, K.; Meckel, M.; Rosch, F.; Sathekge, M. Assessment of Skeletal Metastasis in Prostate Cancer Staging: An Intra-Individual Comparison of ⁶⁸Ga-PSMA PET/CT, ⁶⁸Ga-NODAGA-Zoledronate PET/CT, and ⁹⁹mTc-MDP Bone Scan. *J. Nucl. Med.* **2020**, *61*, 1256.

144. Lawal, I.O.; Mokoala, K.M.G.; Mahapane, J.; Kleyhans, J.; Meckel, M.; Vorster, M.; Ebenhan, T.; Rösch, F.; Sathekge, M.M. A Prospective Intra-Individual Comparison of [⁶⁸Ga]Ga-PSMA-11 PET/CT, [⁶⁸Ga]Ga-NODAGAZOL PET/CT, and [⁹⁹mTc]Tc-MDP Bone Scintigraphy for Radionuclide Imaging of Prostate Cancer Skeletal Metastases. *Eur. J. Nucl. Med. Mol. Imaging* **2021**, *48*, 134–142. [CrossRef]

145. Ndlovu, H.; Lawal, I.; Popoola, G.; Brits, B.; Mokoala, K.; Mahapane, J.; Davis, C.; Sathekge, M. PET Imaging of Atherosclerotic Plaque Calcification with [⁶⁸Ga]Ga-NODAGAZOL: Correlation of Uptake with Cardiovascular Risk Profile of Patients. *J. Nucl. Med.* **2022**, *63*, 2222.

146. Ndlovu, H.; Lawal, I.O.; Popoola, G.O.; Brits, B.; Mokoala, K.M.G.; Maserumule, L.C.; Hlongwa, K.N.; Mahapane, J.; Davis, C.; Sathekge, M.M. [⁶⁸Ga]Ga-NODAGAZOL Uptake in Atherosclerotic Plaques Correlates with the Cardiovascular Risk Profile of Patients. *Ann. Nucl. Med.* **2022**, *36*, 684–692. [CrossRef] [PubMed]

147. Fersing, C.; Bouhlel, A.; Cantelli, C.; Garrigue, P.; Lisowski, V.; Guillet, B. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [¹⁸F]Fluoride: Will [¹⁸F]AlF Replace 68Ga for Metal Chelate Labeling? *Molecules* **2019**, *24*, 2866. [CrossRef] [PubMed]

148. Hassan, H.; Othman, M.F.; Abdul Razak, H.R.; Zakaria, Z.A.; Ahmad Saad, F.F.; Osman, M.A.; Yi, L.H.; Ashhar, Z.; Idris, J.; Abdul Hamid, M.H.N.; et al. Preparation, Optimisation, and In Vitro Evaluation of [¹⁸F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET. *Molecules* **2022**, *27*, 7969. [CrossRef] [PubMed]

149. Fersing, C.; Masurier, N.; Rubira, L.; Deshayes, E.; Lisowski, V. AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. *Pharmaceuticals* **2022**, *15*, 234. [CrossRef]

150. Wu, Z.; Zha, Z.; Choi, S.R.; Plössl, K.; Zhu, L.; Kung, H.F. New 68Ga-PhenA Bisphosphonates as Potential Bone Imaging Agents. *Nucl. Med. Biol.* **2016**, *43*, 360–371. [CrossRef]

151. Kubícek, V.; Rudovský, J.; Kotek, J.; Hermann, P.; Vander Elst, L.; Muller, R.N.; Kolar, Z.I.; Wolterbeek, H.T.; Peters, J.A.; Lukes, I. A Bisphosphonate Monoamide Analogue of DOTA: A Potential Agent for Bone Targeting. *J. Am. Chem. Soc.* **2005**, *127*, 16477–16485. [CrossRef]

152. Fellner, M.; Biesalski, B.; Bausbacher, N.; Kubícek, V.; Hermann, P.; Rösch, F.; Thews, O. ⁶⁸Ga-BPAMD: PET-Imaging of Bone Metastases with a Generator Based Positron Emitter. *Nucl. Med. Biol.* **2012**, *39*, 993–999. [CrossRef]

153. Fellner, M.; Baum, R.P.; Kubícek, V.; Hermann, P.; Lukes, I.; Prasad, V.; Rösch, F. PET/CT Imaging of Osteoblastic Bone Metastases with ⁶⁸Ga-Bisphosphonates: First Human Study. *Eur. J. Nucl. Med. Mol. Imaging* **2010**, *37*, 834. [CrossRef]

154. Mueller, D.; Klette, I.; Baum, R. Clinical Routine Production of ¹⁷⁷Lu-BPAMD. *J. Nucl. Med.* **2013**, *54*, 1191.

155. Meckel, M.; Nauth, A.; Timpe, J.; Zhernosekov, K.; Puranik, A.D.; Baum, R.P.; Rösch, F. Development of a [177Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy. *Cancer Biother. Radiopharm.* **2015**, *30*, 94–99. [CrossRef] [PubMed]

156. Bergmann, R.; Meckel, M.; Kubíček, V.; Pietzsch, J.; Steinbach, J.; Hermann, P.; Rösch, F. ¹⁷⁷Lu-Labelled Macrocyclic Bisphosphonates for Targeting Bone Metastasis in Cancer Treatment. *EJNMMI Res.* **2016**, *6*, 5. [CrossRef] [PubMed]

157. Fellner, M.; Baum, R.; Kubicek, V.; Hermann, P.; Roesch, F. ¹⁷⁷Lu-BPAMD—From Bone Imaging to Therapy with a Macrocycle-Bisphosphonate Ligand. *J. Nucl. Med.* **2010**, *51*, 1164.

158. Pfannkuchen, N.; Meckel, M.; Bergmann, R.; Bachmann, M.; Bal, C.; Sathekge, M.; Mohnike, W.; Baum, R.P.; Rösch, F. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. *Pharmaceuticals* **2017**, *10*, 45. [CrossRef] [PubMed]

159. Yousefnia, H.; Zolghadri, S.; Sadeghi, H.R.; Naderi, M.; Jalilian, A.R.; Shanehsazzadeh, S. Preparation and Biological Assessment of 177Lu-BPAMD as a High Potential Agent for Bone Pain Palliation Therapy: Comparison with ¹⁷⁷Lu-EDTMP. *J. Radioanal. Nucl. Chem.* **2016**, *307*, 1243–1251. [CrossRef]

160. Meckel, M.; Kubíček, V.; Hermann, P.; Miederer, M.; Rösch, F. A DOTA Based Bisphosphonate with an Albumin Binding Moiety for Delayed Body Clearance for Bone Targeting. *Nucl. Med. Biol.* **2016**, *43*, 670–678. [CrossRef] [PubMed]

161. Velikyan, I. Prospective of ⁶⁸Ga-Radiopharmaceutical Development. *Theranostics* **2013**, *4*, 47–80. [CrossRef]

162. Wang, Y.; Wang, Q.; Chen, Z.; Yang, J.; Liu, H.; Peng, D.; Lei, L.; Liu, L.; Wang, L.; Xing, N.; et al. Preparation, Biological Characterization and Preliminary Human Imaging Studies of ⁶⁸Ga-DOTA-IBA. *Front. Oncol.* **2022**, *12*, 1027792. [CrossRef]

163. Yang, J.; Deng, J.; Fan, D.; Chen, G.; Lu, Z.; Liu, H.; Mok, G.S.P.; Chen, Y. Biodistribution and Internal Dosimetry of 68Ga-DOTA-IBA PET Imaging for Patients with Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 847–852. [CrossRef]

164. Wang, Q.; Yang, J.; Wang, Y.; Liu, H.; Feng, Y.; Qiu, L.; Chen, Y. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. *Mol. Pharm.* **2023**, *20*, 1788–1795. [CrossRef]

165. Qiu, L.; Wang, Y.; Liu, H.; Wang, Q.; Chen, L.; Liu, L.; Wang, L.; Feng, Y.; Chen, Y. Safety and Efficacy of 68Ga- or ¹⁷⁷Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases: A Phase 0/I Study. *Clin. Nucl. Med.* **2023**, *48*, 489. [CrossRef] [PubMed]

166. Li, H.; Xu, T.; Hua, Q.; Wang, L.; Chen, Y. 177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 740. [CrossRef] [PubMed]
167. Xu, T.; Qu, G.; Liu, G.; Wang, L.; Chen, Y. A New Radiopharmaceutical $^{225}$Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 650. [CrossRef] [PubMed]

168. Meckel, M.; Bergmann, R.; Miederer, M.; Roesch, F. Bone Targeting Compounds for Radiotherapy and Imaging: *Me(III)-DOTA Conjugates of Bisphosphonic Acid, Pamidronic Acid and Zoledronic Acid. *EJNMMI Radiopharm. Chem.* **2017**, *1*, 14. [CrossRef] [PubMed]

169. Ogawa, K.; Kawashima, H.; Shiba, K.; Washiyama, K.; Yoshimoto, M.; Kiyono, Y.; Ueda, M.; Mori, H.; Saji, H. Development of [(90)Y]DOTA-Conjugated Bisphosphonate for Treatment of Painful Bone Metastases. *Nucl. Med. Biol.* **2009**, *36*, 129–135. [CrossRef]

170. Ogawa, K.; Takai, K.; Kanbara, H.; Kiwada, T.; Kitamura, Y.; Shiba, K.; Odani, A. Preparation and Evaluation of a Radiogallium Complex-Conjugated Bisphosphonate as a Bone Scintigraphy Agent. *Nucl. Med. Biol.* **2011**, *38*, 631–636. [CrossRef] [PubMed]

171. Fakhari, A.; Jalilian, A.R.; Johari-Daha, F.; Shafiee-Ardestani, M.; Khalaj, A. Preparation and Biological Study of $^{68}$Ga-DOTA-Alendronate. *Asia. Ocean J. Nucl. Med. Biol.* **2016**, *4*, 98–105. [CrossRef] [PubMed]

172. Ahrens, B.J.; Li, L.; Ciminera, A.K.; Chea, J.; Poku, E.; Bading, J.R.; Weist, M.R.; Miller, M.M.; Colcher, D.M.; Shively, J.E. Diagnostic PET Imaging of Mammary Microcalcifications Using $^{64}$Cu-DOTA-Alendronate in a Rat Model of Breast Cancer. *J. Nucl. Med.* **2017**, *58*, 1373–1379. [CrossRef]

173. Ballinger, J.R. 68Ga-DOTA-Zoledronate. In *PET Radiopharmaceuticals*; Springer International Publishing: Cham, Switzerland, 2022; pp. 62–63. ISBN 978-3-031-10270-7.

174. Grun, A.; Kovacs, R.; Nagy, D.I.; Garadnay, S.; Greiner, I.; Keglevich, G. Efficient Synthesis of Benzidronate Applying of Phosphorus Trichloride and Phosphorous Acid. *Lett. Drug. Des. Discov.* **2015**, *12*, 78–84. [CrossRef]

175. Grus, T.; Lahnif, H.; Klasen, B.; Moon, E.-S.; Greifenstein, L.; Roesch, F. Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy. *Bioconjug. Chem.* **2021**, *32*, 1223–1231. [CrossRef]

176. Greifenstein, L.; Engelbogen, N.; Máthé, D.; Grus, T.; Rösch, F.; Bergmann, R. Squaric Acid Bisphosphonates for Theranostics of Bone Metastasis—The Easy DOTA-Zoledronate. *Front. Nucl. Med.* **2022**, *2*, 870910. [CrossRef]

177. Khawar, A.; Eppard, E.; Roesch, F.; Ahmadzadehfar, H.; Kürpig, S.; Meisenheimer, M.; Gaertner, F.C.; Essler, M.; Bundschuh, R.A. Preliminary Results of Biodistribution and Dosimetric Analysis of [ $^{68}$Ga]Ga-DOTAZOL: A New Zoledronate-Based Bisphosphonate for PET/CT Diagnosis of Bone Diseases. *Ann. Nucl. Med.* **2019**, *33*, 404–413. [CrossRef]

178. Meisenheimer, M.; Kürpig, S.; Essler, M.; Eppard, E. DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine. *Molecules* **2020**, *25*, 2988. [CrossRef] [PubMed]

179. Pillai, S.A.; Chobisa, D.; Urimi, D.; Ravindra, N. Pharmaceutical Glass Interactions: A Review of Possibilities. *J. Pharm. Sci.* **2016**, *8*, 103–111.

180. Meckel, M.; Fellner, M.; Thieme, N.; Bergmann, R.; Kubicek, V.; Rösch, F. In Vivo Comparison of DOTA Based $^{68}$Ga-Labelled Bisphosphonates for Bone Imaging in Non-Tumour Models. *Nucl. Med. Biol.* **2013**, *40*, 823–830. [CrossRef] [PubMed]

181. Eppard, E.; Meisenheimer, M.; Fuente, A.D.L.; Kurpig, S.; Essler, M.; Roesch, F. Radiolabelling of DOTAMZOL with $^{68}$Ga and $^{44}$Sc for Clinical Application. *EJEA* **2016**, *47*, OC34. [CrossRef]

182. Khawar, A.; Eppard, E.; Roesch, F.; Ahmadzadehfar, H.; Kürpig, S.; Meisenheimer, M.; Gaertner, F.C.; Essler, M.; Bundschuh, R.A. Biodistribution and Post-Therapy Dosimetric Analysis of [ $^{177}$Lu]Lu-DOTAZOL in Patients with Osteoblastic Metastases: First Results. *EJNMMI Res.* **2019**, *9*, 102. [CrossRef]

183. Yadav, M.P.; Ballal, S.; Meckel, M.; Roesch, F.; Bal, C. [ $^{177}$Lu]Lu-DOTA-ZOL Bone Pain Palliation in Patients with Skeletal Metastases from Various Cancers: Efficacy and Safety Results. *EJNMMI Res.* **2020**, *10*, 130. [CrossRef]

184. Kreppel, B.; Gaertner, F.C.; Ahmadzadehfar, H.; Khawar, A.; Roesch, F.; Kürpig, S.; Meisenheimer, M.; Essler, M.; Bundschuh, R.A. [177Lu]Lu-DOTA-Zoledronate Therapy—First Application in a Patient with Primary Osseous Metastatic Bronchial Carcinoma. *Nuklearmedizin* **2020**, *59*, 281–283. [CrossRef]

185. Clarke, E.T.; Martell, A.E. Stabilities of Trivalent Metal Ion Complexes of the Tetraacetate Derivatives of 12-, 13- and 14-Membered Tetraazamacycles. *Inorganica Chim. Acta.* **1991**, *190*, 37–46. [CrossRef]

186. Kubíček, V.; Havlíčková, J.; Kotek, J.; Tircsó, G.; Hermann, P.; Tóth, É.; Lukeš, I. Gallium(III) Complexes of DOTA and DOTA-Monoamide: Kinetic and Thermodynamic Studies. *Inorg. Chem.* **2010**, *49*, 10960–10969. [CrossRef] [PubMed]

187. Eryilmaz, K.; Bakar, H.E.; Kilbas, B. Novel Developed HPLC Analyses of [ $^{68}$Ga]Ga/[ $^{177}$Lu]Lu-EDTMP and [ $^{68}$Ga]Ga/[ $^{177}$Lu]Lu-DOTA-Zoledronate. *J. Label Comp. Radiopharm.* **2022**, *65*, 178–186. [CrossRef] [PubMed]

188. Pfannkuchen, N.; Bausbacher, N.; Pektor, S.; Miederer, M.; Rosch, F. In Vivo Evaluation of [ $^{225}$Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases. *Curr. Radiopharm.* **2018**, *11*, 223–230. [CrossRef]

189. Park, E.A.; Graves, S.A.; Menda, Y. The Impact of Radiopharmaceutical Therapy on Renal Function. *Semin. Nucl. Med.* **2022**, *52*, 467–474. [CrossRef] [PubMed]

190. Zhang, J.; Singh, A.; Kulkarni, H.R.; Schuchardt, C.; Müller, D.; Wester, H.-J.; Maina, T.; Rösch, F.; van der Meulen, N.P.; Müller, C.; et al. From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies. *Semin. Nucl. Med.* **2019**, *49*, 422–437. [CrossRef] [PubMed]

191. International Atomic Energy Agency. Pain Palliation of Bone Metastases: Production, Quality Control and Dosimetry of Radiopharmaceuticals, IAEA Radioisotopes and Radiopharmaceuticals Series No.9 [IAEA Preprint]. 2021. Available online: https://Preprint.Iaea.Org/Search.Aspx?orig_q=RN:54079457 (accessed on 3 December 2023).
167. Xu, T.; Qu, G.; Liu, G.; Wang, L.; Chen, Y. A New Radiopharmaceutical $^{225}$Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases. *Clin. Nucl. Med.* **2023**, *48*, 650. [CrossRef] [PubMed]

168. Meckel, M.; Bergmann, R.; Miederer, M.; Roesch, F. Bone Targeting Compounds for Radiotherapy and Imaging: *Me(III)-DOTA Conjugates of Bisphosphonic Acid, Pamidronic Acid and Zoledronic Acid. *EJNMMI Radiopharm. Chem.* **2017**, *1*, 14. [CrossRef] [PubMed]

169. Ogawa, K.; Kawashima, H.; Shiba, K.; Washiyama, K.; Yoshimoto, M.; Kiyono, Y.; Ueda, M.; Mori, H.; Saji, H. Development of [(90)Y]DOTA-Conjugated Bisphosphonate for Treatment of Painful Bone Metastases. *Nucl. Med. Biol.* **2009**, *36*, 129-135. [CrossRef]

170. Ogawa, K.; Takai, K.; Kanbara, H.; Kiwada, T.; Kitamura, Y.; Shiba, K.; Odani, A. Preparation and Evaluation of a Radiogallium Complex-Conjugated Bisphosphonate as a Bone Scintigraphy Agent. *Nucl. Med. Biol.* **2011**, *38*, 631-636. [CrossRef] [PubMed]

171. Fakhari, A.; Jalilian, A.R.; Johari-Daha, F.; Shafiee-Ardestani, M.; Khalaj, A. Preparation and Biological Study of $^{68}$Ga-DOTA-Alendronate. *Asia. Ocean J. Nucl. Med. Biol.* **2016**, *4*, 98-105. [CrossRef] [PubMed]

172. Ahrens, B.J.; Li, L.; Ciminera, A.K.; Chea, J.; Poku, E.; Bading, J.R.; Weist, M.R.; Miller, M.M.; Colcher, D.M.; Shively, J.E. Diagnostic PET Imaging of Mammary Microcalcifications Using $^{64}$Cu-DOTA-Alendronate in a Rat Model of Breast Cancer. *J. Nucl. Med.* **2017**, *58*, 1373-1379. [CrossRef]

173. Ballinger, J.R. 68Ga-DOTA-Zoledronate. In *PET Radiopharmaceuticals*, Springer International Publishing: Cham, Switzerland, 2022; pp. 62-63. ISBN 978-3-031-10270-7.

174. Grun, A.; Kovacs, R.; Nagy, D.I.; Garadnay, S.; Greiner, I.; Keglevich, G. Efficient Synthesis of Benzidronate Applying of Phosphorus Trichloride and Phosphorous Acid. *Lett. Drug. Des. Discov.* **2015**, *12*, 78-84. [CrossRef]

175. Grus, T.; Lahnif, H.; Klasen, B.; Moon, E.-S.; Greifenstein, L.; Roesch, F. Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy. *Bioconjug. Chem.* **2021**, *32*, 1223-1231. [CrossRef]

176. Greifenstein, L.; Engelbogen, N.; Máthé, D.; Grus, T.; Rösch, F.; Bergmann, R. Squaric Acid Bisphosphonates for Theranostics of Bone Metastasis—The Easy DOTA-Zoledronate. *Front. Nucl. Med.* **2022**, *2*, 870910. [CrossRef]

177. Khawar, A.; Eppard, E.; Roesch, F.; Ahmadzadehfar, H.; Kürpig, S.; Meisenheimer, M.; Gaertner, F.C.; Essler, M.; Bundschuh, R.A. Preliminary Results of Biodistribution and Dosimetric Analysis of [ $^{68}$Ga]Ga-DOTAZOL: A New Zoledronate-Based Bisphosphonate for PET/CT Diagnosis of Bone Diseases. *Ann. Nucl. Med.* **2019**, *33*, 404-413. [CrossRef]

178. Meisenheimer, M.; Kürpig, S.; Essler, M.; Eppard, E. DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine. *Molecules* **2020**, *25*, 2988. [CrossRef] [PubMed]

179. Pillai, S.A.; Chobisa, D.; Urimi, D.; Ravindra, N. Pharmaceutical Glass Interactions: A Review of Possibilities. *J. Pharm. Sci.* **2016**, *8*, 103-111.

180. Meckel, M.; Fellner, M.; Thieme, N.; Bergmann, R.; Kubicek, V.; Rösch, F. In Vivo Comparison of DOTA Based $^{68}$Ga-Labelled Bisphosphonates for Bone Imaging in Non-Tumour Models. *Nucl. Med. Biol.* **2013**, *40*, 823-830. [CrossRef] [PubMed]

181. Eppard, E.; Meisenheimer, M.; Fuente, A.D.L.; Kurpig, S.; Essler, M.; Roesch, F. Radiolabelling of DOTAMZOL with $^{68}$Ga and $^{44}$Sc for Clinical Application. *EJEA* **2016**, *47*, OC34. [CrossRef]

182. Khawar, A.; Eppard, E.; Roesch, F.; Ahmadzadehfar, H.; Kürpig, S.; Meisenheimer, M.; Gaertner, F.C.; Essler, M.; Bundschuh, R.A. Biodistribution and Post-Therapy Dosimetric Analysis of [ $^{177}$Lu]Lu-DOTAZOL in Patients with Osteoblastic Metastases: First Results. *EJNMMI Res.* **2019**, *9*, 102. [CrossRef]

183. Yadav, M.P.; Ballal, S.; Meckel, M.; Roesch, F.; Bal, C. [ $^{177}$Lu]Lu-DOTA-ZOL Bone Pain Palliation in Patients with Skeletal Metastases from Various Cancers: Efficacy and Safety Results. *EJNMMI Res.* **2020**, *10*, 130. [CrossRef]

184. Kreppel, B.; Gaertner, F.C.; Ahmadzadehfar, H.; Khawar, A.; Roesch, F.; Kürpig, S.; Meisenheimer, M.; Essler, M.; Bundschuh, R.A. [177Lu]Lu-DOTA-Zoledronate Therapy—First Application in a Patient with Primary Osseous Metastatic Bronchial Carcinoma. *Nuklearmedizin* **2020**, *59*, 281-283. [CrossRef]

185. Clarke, E.T.; Martell, A.E. Stabilities of Trivalent Metal Ion Complexes of the Tetraacetate Derivatives of 12-, 13- and 14-Membered Tetraazamacycles. *Inorganica Chim. Acta.* **1991**, *190*, 37-46. [CrossRef]

186. Kubíček, V.; Havlíčková, J.; Kotek, J.; Tircsó, G.; Hermann, P.; Tóth, É.; Lukeš, I. Gallium(III) Complexes of DOTA and DOTA-Monoamide: Kinetic and Thermodynamic Studies. *Inorg. Chem.* **2010**, *49*, 10960-10969. [CrossRef] [PubMed]

187. Eryilmaz, K.; Bakar, H.E.; Kilbas, B. Novel Developed HPLC Analyses of [ $^{68}$Ga]Ga/[ $^{177}$Lu]Lu-EDTMP and [ $^{68}$Ga]Ga/[ $^{177}$Lu]Lu-DOTA-Zoledronate. *J. Label Comp. Radiopharm.* **2022**, *65*, 178-186. [CrossRef] [PubMed]

188. Pfannkuchen, N.; Bausbacher, N.; Pektor, S.; Miederer, M.; Rosch, F. In Vivo Evaluation of [ $^{225}$Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases. *Curr. Radiopharm.* **2018**, *11*, 223-230. [CrossRef]

189. Park, E.A.; Graves, S.A.; Menda, Y. The Impact of Radiopharmaceutical Therapy on Renal Function. *Semin. Nucl. Med.* **2022**, *52*, 467-474. [CrossRef] [PubMed]

190. Zhang, J.; Singh, A.; Kulkarni, H.R.; Schuchardt, C.; Müller, D.; Wester, H.-J.; Maina, T.; Rösch, F.; van der Meulen, N.P.; Müller, C.; et al. From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies. *Semin. Nucl. Med.* **2019**, *49*, 422-437. [CrossRef] [PubMed]

191. International Atomic Energy Agency. Pain Palliation of Bone Metastases: Production, Quality Control and Dosimetry of Radiopharmaceuticals, IAEA Radioisotopes and Radiopharmaceuticals Series No.9 [IAEA Preprint]. 2021. Available online: https://Preprint.Iaea.Org/Search.Aspx?orig_q=RN:54079457 (accessed on 3 December 2023).
192. Kabasakal, L.; AbuQbeitah, M.; Aygün, A.; Yeyin, N.; Ocak, M.; Demirci, E.; Toklu, T. Pre-Therapeutic Dosimetry of Normal Organs and Tissues of 177Lu-PSMA-617 Prostate-Specific Membrane Antigen (PSMA) Inhibitor in Patients with Castration-Resistant Prostate Cancer. *Eur. J. Nucl. Med. Mol. Imaging* **2015**, *42*, 1976–1983. [CrossRef]

193. Scarpa, L.; Buxbaum, S.; Kendler, D.; Fink, K.; Bektic, J.; Gruber, L.; Decristoforo, C.; Uprimny, C.; Lukas, P.; Horninger, W.; et al. The ⁶⁸Ga/¹⁷⁷Lu Theragnostic Concept in PSMA Targeting of Castration-Resistant Prostate Cancer: Correlation of SUVmax Values and Absorbed Dose Estimates. *Eur. J. Nucl. Med. Mol. Imaging* **2017**, *44*, 788–800. [CrossRef]

194. Fernández, R.; Eppard, E.; Lehnert, W.; Jiménez-Franco, L.D.; Soza-Ried, C.; Ceballos, M.; Ribbeck, J.; Kluge, A.; Rösch, F.; Meckel, M.; et al. Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases. *J. Nucl. Med.* **2021**, *62*, 1126–1132. [CrossRef]

195. Rubira, L.; Deshayes, E.; Santoro, L.; Kotzki, P.O.; Fersing, C. 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic. *Pharmaceutics* **2023**, *15*, 1051. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
192. Kabasakal, L.; AbuQbeitah, M.; Aygün, A.; Yeyin, N.; Ocak, M.; Demirci, E.; Toklu, T. Pre-Therapeutic Dosimetry of Normal Organs and Tissues of 177Lu-PSMA-617 Prostate-Specific Membrane Antigen (PSMA) Inhibitor in Patients with Castration-Resistant Prostate Cancer. *Eur. J. Nucl. Med. Mol. Imaging* **2015**, *42*, 1976–1983. [CrossRef]

193. Scarpa, L.; Buxbaum, S.; Kendler, D.; Fink, K.; Bektic, J.; Gruber, L.; Decristoforo, C.; Uprimny, C.; Lukas, P.; Horninger, W.; et al. The ⁶⁸Ga/¹⁷⁷Lu Theragnostic Concept in PSMA Targeting of Castration-Resistant Prostate Cancer: Correlation of SUVmax Values and Absorbed Dose Estimates. *Eur. J. Nucl. Med. Mol. Imaging* **2017**, *44*, 788–800. [CrossRef]

194. Fernández, R.; Eppard, E.; Lehnert, W.; Jiménez-Franco, L.D.; Soza-Ried, C.; Ceballos, M.; Ribbeck, J.; Kluge, A.; Rösch, F.; Meckel, M.; et al. Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases. *J. Nucl. Med.* **2021**, *62*, 1126–1132. [CrossRef]

195. Rubira, L.; Deshayes, E.; Santoro, L.; Kotzki, P.O.; Fersing, C. 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic. *Pharmaceutics* **2023**, *15*, 1051. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.